How to Value a Medical Device Distributor in 2026

Medical device distribution is one of the most misunderstood niches in healthcare M&A. From the outside it looks like a simple reseller business — buy from the manufacturer, mark it up, sell to the hospital. In reality, the value of a medical device distributor is tied almost entirely to two things most sellers don't bring to the table early enough: the exclusivity language in their manufacturer contracts, and the stickiness of their hospital GPO relationships.

I've worked on distributor deals ranging from $3M enterprise value up through nine-figure platform acquisitions. The pricing framework is surprisingly consistent, but the outcomes vary by millions depending on factors that have nothing to do with last year's EBITDA.

The Multiple Range: 4-7x EBITDA

Med device distributors trade in a fairly tight band of 4-7x adjusted EBITDA, with a few outliers on either end. Where you fall inside that range depends almost entirely on contract quality and category focus.

• 4.0-4.5x EBITDA: Non-exclusive distributors, commodity categories (gloves, gowns, basic surgical supplies), concentrated customer base, manufacturer contracts under 3 years remaining.
• 5.0-5.5x EBITDA: The bread and butter — regional distributor, semi-exclusive lines, diversified hospital customer base, stable mid-single-digit growth.
• 6.0-7.0x EBITDA: Exclusive territory rights on branded implantables or capital equipment, national GPO contracts (Vizient, Premier, HealthTrust), $20M+ revenue, 8%+ organic growth.
• 7x+: Rare, and usually reserved for distributors that look more like specialty sales organizations — think exclusive U.S. distribution rights for a growing European device maker.

For deals under $5M in EBITDA, you'll also see SDE-based pricing from individual buyers, typically 2.5-3.5x SDE. Above $5M EBITDA, it's almost always a strategic or PE-backed buyer paying on EBITDA.

Why Manufacturer Contracts Drive 40% of Value

Here's the brutal reality of this industry: you don't own your revenue. The manufacturer does. Every buyer who looks at a medical device distributor starts diligence by reading your distribution agreements line by line, because those contracts can be terminated on change of control — and often are.

I've seen distributors with $4M in EBITDA get wildly different offers based entirely on what their Boston Scientific, Medtronic, or Johnson & Johnson contracts said. One client had a clean 5-year exclusive territory agreement with auto-renewal and no change-of-control clause. He sold for 6.5x. Another client, same size, had a contract that allowed the manufacturer to terminate with 90 days notice upon any ownership change. He got 4.2x, and the buyer insisted on a $1.5M holdback tied to contract reaffirmation post-close.

Before you go to market, get your contract portfolio reviewed by healthcare M&A counsel. If you have change-of-control triggers, try to renegotiate them — or at minimum, get verbal comfort from your manufacturer reps that they won't pull the line. Buyers will verify those conversations during diligence, so don't oversell what you don't have.

The GPO Contract Factor

Group purchasing organizations — Vizient, Premier, HealthTrust Performance Group, and Intalere — control access to the majority of U.S. hospital purchasing. If your distributor has GPO contracts, you have distribution channels into thousands of hospitals automatically. If you don't, you're selling hospital by hospital.

A distributor on the Vizient contract for a high-volume category can be worth 1.0-1.5 turns of EBITDA more than an equivalent distributor without GPO access. The reason is simple: the acquirer inherits the contract and immediately has a distribution platform they can layer additional products onto. Strategic buyers like Cardinal Health, Owens & Minor, and Medline will pay meaningful premiums for distributors whose GPO relationships expand their own shelf space.

Pay attention to contract tier. Being a committed supplier on a GPO contract (where hospitals have compliance obligations) is dramatically more valuable than being an awarded supplier on a multi-source contract where hospitals can buy from any of six vendors.

Calculating Adjusted EBITDA for a Distributor

Distributors tend to have messy income statements because owners often run personal expenses through the business and pay themselves in ways that distort profitability. Your adjusted EBITDA calculation is where the real negotiation happens.

The add-backs I see most frequently in distributor deals:

• Owner compensation normalization: Replace the owner's salary with market comp for a GM or VP of Sales, typically $180-250K.
• Family members on payroll: Spouses and adult children who don't work in the business full-time.
• Company vehicles: The owner's F-150 and the spouse's Lexus don't need to stay.
• One-time legal and consulting: Contract disputes, regulatory consulting, territory expansion studies.
• Rent normalization: If you own the warehouse through a separate LLC and charge the business below-market rent, the buyer will normalize to market.

Be disciplined. Aggressive add-backs that get thrown out during diligence destroy trust and lead to re-traded deal terms.

Who Actually Buys Medical Device Distributors

The buyer universe for device distributors is smaller than most sellers realize, which is both good and bad. Good because it means well-run processes command real competition. Bad because the wrong buyer approach can leave millions on the table.

Strategic distributors: Cardinal Health, Medline, Owens & Minor, McKesson Medical-Surgical, and Henry Schein all buy regional and specialty distributors to fill gaps in their product portfolio or geography. They typically pay the top of the range when the target fits cleanly into an underserved category.

Manufacturer acquisitions: Occasionally a device manufacturer will buy its own distributor to go direct. This is rare but usually produces the highest multiples — I've seen 8-9x in situations where the manufacturer decided independent distribution was strategically untenable.

Private equity platforms: Audax, Court Square, Linden Capital, and Shore Capital all have active med device distribution platforms. They pay 5-7x for platform-quality businesses ($5M+ EBITDA, multi-state, diversified manufacturer mix) and 4-5x for add-ons.

Search funds and independent sponsors: Increasingly active in the $1-3M EBITDA range, typically paying 4-5x.

What Kills Distributor Value

Customer concentration. If your top 5 hospitals represent more than 40% of revenue, every buyer will apply a discount. One IDN system can switch distributors on 90 days notice. I've seen buyers walk away entirely when top-customer concentration exceeded 35%.

Manufacturer concentration. Same risk on the other side. If 60% of your gross profit comes from one manufacturer, that manufacturer effectively controls your valuation. Diversification across 4-6 core lines materially expands your buyer pool.

Aged inventory and slow-moving SKUs. Buyers will hit you on working capital. Clean up obsolete inventory 12 months before going to market. Every dollar of dead inventory typically reduces purchase price by a dollar.

Regulatory skeletons. FDA warning letters, failed audits, off-label marketing issues, or sunshine act disclosure problems will tank your deal. Address these before a buyer's diligence team finds them.

How to Maximize Value Before Selling

Three moves matter most in the 18-24 months before you go to market.

Lock in your manufacturer contracts. Renegotiate exclusive territory rights. Extend terms to 5+ years. Get change-of-control clauses removed or softened. This single initiative can add a full turn of EBITDA to your valuation.

Diversify your hospital base. If your top customer is 25%+ of revenue, invest in sales capacity to grow the long tail. Every point of concentration you remove buys you price protection.

Professionalize your reporting. GP margin by manufacturer, by SKU, by customer, by rep. Sales pipeline data. Quality-compliant financial statements. Buyers pay more for businesses where they can see the numbers clearly. Lean on our pre-sale preparation guide for the full checklist.

The Bottom Line

Medical device distribution can be a spectacular exit or a disappointing one, and the difference usually comes down to preparation. The distributors that sell at 6.5-7x didn't get there by accident — they spent two years tightening manufacturer contracts, diversifying customers, and cleaning up their books. If you're 24 months from selling, start that work now.